Beam Therapeutics adds new CLO Bellon to its management team
Biotech medicines developer Beam Therapeutics, based in Cambridge, Massachusetts, has a new chief legal officer, Christine Bellon. The small company specializes in medicines that edit a patient’s DNA.
Bellon has more than 25 years of experience in the life science industry. Prior to joining Beam, she was senior vice president, general counsel and corporate secretary for Forma Therapeutics, where she built a legal team, negotiated changes to the company’s operating structure, and played a key role in negotiations with Forma’s strategic partner. Before that, Bellon was senior vice president of legal affairs for Relay Therapeutics, where she helped obtain foundational partnerships for the company and formulated its intellectual property strategy. She was also vice president of legal affairs and corporate secretary at Blueprint Medicines, where she built ts global IP portfolio and worked on its initial public offering.
Bellon holds a B.S. in chemistry from Yale University; a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, where she did research in the laboratory of K. Barry Sharpless; and a J.D. from Columbia Law School. Dr. Bellon is a trustee of the Boston Museum of Science.
“In the past year, we have made tremendous progress in advancing the research and preclinical development of our base editing platform and pipeline. 2019 continues to be a year of significant growth for Beam, and I am very pleased to welcome Christine Bellon,” said John Evans, chief executive officer of Beam, in a release.